Evidence map›Paper›PMID 38868956›Full record

ArticleJournal of extracellular vesicles2024

Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs.

Carlos J Nogueras-Ortiz, Erden Eren, Pamela Yao, Elizabeth Calzada, Christopher Dunn, Olga Volpert, Francheska Delgado-Peraza, Maja Mustapic, Alexey Lyashkov, F Javier Rubio and 8 more

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. microRNA-7-5p and α-Synuclein SAA Predict Parkinson's Disease Phenoconversion.Annals of clinical and translational neurology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Carlos J Nogueras-OrtizLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2503-965X
Erden ErenLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-5190-9500
Pamela YaoLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Elizabeth CalzadaLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Christopher DunnFlow Cytometry Unit, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Olga VolpertNeuroDex Inc., Natick, Maryland, USA.ORCID https://orcid.org/0000-0003-1381-5543
Francheska Delgado-PerazaLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Maja MustapicLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Alexey LyashkovLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
F Javier RubioNeuronal Ensembles in Addiction Section, Behavioral Neuroscience Research Branch, Intramural Research Program/National Institute on Drug Abuse/National Institutes of Health, Baltimore, Maryland, USA.
Michael VreonesLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.ORCID https://orcid.org/0009-0003-1719-8156
Lesley ChengLa Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.
Yang YouDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Andrew F HillLa Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.ORCID https://orcid.org/0000-0001-5581-2354
Tsuneya IkezuDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0002-3979-8596
Erez EitanNeuroDex Inc., Natick, Maryland, USA.
Edward J GoetzlDepartment of Medicine, University of California, San Francisco, California, USA.
Dimitrios KapogiannisLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.

Funding

Studies in Dementia and Neurodegenerative DiseasesZIAAG000975 · NIA · NATIONAL INSTITUTE ON AGING · PI KAPOGIANNIS, DIMITRIOS · 2009 to 2025
$31.5M
Exosome-mediated propagation of pathogenic tau proteinRF1AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2016 to 2021
$5.0M
Extraceullar Vesicle Biomarkers for Prediction of Cognitive Decline, Ab and TAU Accumulation, and atrophy in Preclinical Alzheimer's DiseaseZIAAG000003 · NIA · NATIONAL INSTITUTE ON AGING · PI KAPOGIANNIS, DIMITRIOS · 2022 to 2025
$4.4M
Molecular characterization of extracellular vesicles for the spread of misfolded tau proteinR01AG067763 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$3.1M
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's diseaseR01AG066429 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2020 to 2024
$2.0M
NIA NIH HHS R01 AG066429NIA NIH HHS R01 AG067763NIA NIH HHS RF1 AG054199
6 · The paper itself

Abstract

Isolation of neuron-derived extracellular vesicles (NDEVs) with L1 Cell Adhesion Molecule (L1CAM)-specific antibodies has been widely used to identify blood biomarkers of CNS disorders. However, full methodological validation requires demonstration of L1CAM in individual NDEVs and lower levels or absence of L1CAM in individual EVs from other cells. Here, we used multiple single-EV techniques to establish the neuronal origin and determine the abundance of L1CAM-positive EVs in human blood. L1CAM epitopes of the ectodomain are shown to be co-expressed on single-EVs with the neuronal proteins β-III-tubulin, GAP43, and VAMP2, the levels of which increase in parallel with the enrichment of L1CAM-positive EVs. Levels of L1CAM-positive EVs carrying the neuronal proteins VAMP2 and β-III-tubulin range from 30% to 63%, in contrast to 0.8%-3.9% of L1CAM-negative EVs. Plasma fluid-phase L1CAM does not bind to single-EVs. Our findings support the use of L1CAM as a target for isolating plasma NDEVs and leveraging their cargo to identify biomarkers reflecting neuronal function.

Indexed as

BiomarkersExtracellular VesiclesNeural Cell Adhesion Molecule L1NeuronsVesicle-Associated Membrane Protein 2HumansTubulinBiomarkersL1CAM protein, humanNeural Cell Adhesion Molecule L1TUBB3 protein, humanTubulinVAMP2 protein, humanVesicle-Associated Membrane Protein 2Alzheimer's diseaseblood biomarkersextracellular vesiclesL1CAMneuron‐derived extracellular vesicles

Identifiers

PMID38868956
PMCPMC11170079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.